Major Sub-Saharan ANTICOV Study Drops HCQ & Adopts Nitazoxanide & the Corticosteroid Ciclesonide

Major Sub-Saharan ANTICOV Study Drops HCQ & Adopts Nitazoxanide & the Corticosteroid Ciclesonide

TrialSite introduced the global community to the ANTICOV trial back on November 27, 2020. Sponsored by a consortium of African R&D organizations and international health organizations, the study is led by the Drugs for Neglected Diseases initiative (DNDi). This platform indicated that that multi-national sub-Saharan African study focused on low-cost repurposed drugs started with Hydroxychloroquine. That was apparently changed in December 2020, as the so-called ‘adaptive platform’ and innovative trial, allowing for study drug to be introduced and removed based on results, removed both the anti-malaria drug and the antiretroviral combination of lopinavir/ritonavir as the World Health Organization (WHO) recommended against the use of those drugs for the treatment of COVID-19 patients, including those patients with mild-to-moderate COVID-19. By the start of 2021, the study sponsors swapped out the two replaced drugs with a new potential treatment that combined the well-known anti-parasitic drug nitazoxanide and the inhaled corticosteroid known as ciclesonide. Apparently, the pair of study drugs include a couple of mechanisms of action that could work at different stages of SARS-Co...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee